CEO of Zoetis Inc (30-Year Financial, Insider Trades) Kristin C Peck (insider trades) sold 10,500 shares of ZTS on 08/25/2020 at an average price of $157.61 a share. The total sale was $1.7 million.
Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. Zoetis Inc has a market cap of $75.91 billion; its shares were traded at around $159.76 with a P/E ratio of 47.41 and P/S ratio of 12.10. The dividend yield of Zoetis Inc stocks is 0.48%. Zoetis Inc had annual average EBITDA growth of 53.30% over the past ten years. GuruFocus rated Zoetis Inc the business predictability rank of 2.5-star. GuruFocus has detected 1 severe warning sign with Zoetis Inc. .
CEO Recent Trades:
- CEO Kristin C Peck sold 10,500 shares of ZTS stock on 08/25/2020 at the average price of $157.61. The price of the stock has increased by 1.36% since.
Directors and Officers Recent Trades:
- Executive Vice President Roxanne Lagano sold 6,000 shares of ZTS stock on 08/19/2020 at the average price of $160.37. The price of the stock has decreased by 0.38% since.
- Executive Vice President Catherine A. Knupp sold 13,000 shares of ZTS stock on 08/13/2020 at the average price of $158.86. The price of the stock has increased by 0.57% since.
- Director Willie M Reed sold 1,885 shares of ZTS stock on 08/13/2020 at the average price of $159.07. The price of the stock has increased by 0.43% since.
- Executive Vice President Heidi C. Chen sold 1,179 shares of ZTS stock on 08/03/2020 at the average price of $152.19. The price of the stock has increased by 4.97% since.
For the complete insider trading history of ZTS, click here
.
